ALSO NOTED: Galvus gets EU committee nod; Merck appoints Vanderbilt official to board;

> The European Committee for Medicinal Products gave its blessing to Novartis' new diabetes med Galvus, after the company revised prescribing information to minimize liver-safety problems. The drug will likely be available in Europe during the first half of 2008. Report

> Merck has appointed Dr. Harry Jacobson, vice chancellor for health affairs at Vanderbilt University, to its board of directors, effective Tuesday. Report

> Genzyme said the FDA has broadened the use of its thyroid cancer diagnostic tool Thyrogen to include identification of cancerous residue in patients who have had their thyroids removed. Release

And Finally... Patients who fail to respond to the ovarian cancer treatment Paclitaxel lack a specific protein, according to a new study. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.